<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026905</url>
  </required_header>
  <id_info>
    <org_study_id>T5221</org_study_id>
    <nct_id>NCT05026905</nct_id>
  </id_info>
  <brief_title>A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gemcitabine and nab-paclitaxel are one standard of care for metastatic pancreatic&#xD;
      adenocarcinoma (mPDAC) but the progression free survival (PFS) of the regimen is only 5.5&#xD;
      months. Previous phase II study showed gemcitabine and nab-paclitaxel plus cisplatin had a&#xD;
      PFS of 10.1 months in mPDAC. However, the nephrotoxicity of cisplatin is always a concern&#xD;
      therefore cisplatin was substituted with oxaliplatin in current study. S-1 monotherapy has&#xD;
      shown promising anti-tumor activity against PDAC with a manageable safety profile which&#xD;
      provided the opportunity of combination with other agents. In this study, we will evaluate&#xD;
      the efficacy and safety of gemcitabine, nab-paclitaxel plus S-1/LV (GASL) against&#xD;
      gemcitabine, nab-paclitaxel plus oxaliplatin (GAP) in patients with mPDAC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>6 years</time_frame>
    <description>tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>6 years</time_frame>
    <description>Defined as having complete response, partial response or stable disease at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>6 years</time_frame>
    <description>from the start date of study treatment to the date of progression disease or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 years</time_frame>
    <description>from the start date of study treatment to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>6 years</time_frame>
    <description>time from documentation of tumor response to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>6 years</time_frame>
    <description>Safety profile will be recorded and graded according to NCI-CTCAE v 5.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Phase II, Open-label, Parallel 2-arm, Multi-center</condition>
  <arm_group>
    <arm_group_label>GASL arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>eligible patients will receive gemcitabine 800 mg/m2 on day 1, nab-paclitaxel 125 mg/m2 on day 1, S-1 orally 60-100 mg/day [depending on patient's baseline body surface area (BSA)] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:&#xD;
BSA &lt; 1.25 m2: 60 mg/day&#xD;
1.25 m2 ≤ BSA &lt; 1.5 m2: 80 mg/day&#xD;
BSA ≥ 1.5 m2: 100 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAP arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>eligible patients will receive gemcitabine 800 mg/m2, nab-paclitaxel 125 mg/m2 and oxaliplatin 75mg/m2 on day 1 in a 2-week cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.</description>
    <arm_group_label>GAP arm</arm_group_label>
    <arm_group_label>GASL arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine</description>
    <arm_group_label>GAP arm</arm_group_label>
    <arm_group_label>GASL arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 orally 60-100 mg/day day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:&#xD;
BSA &lt; 1.25 m2: 60 mg/day&#xD;
1.25 m2 ≤ BSA &lt; 1.5 m2: 80 mg/day&#xD;
BSA ≥ 1.5 m2: 100 mg/day</description>
    <arm_group_label>GASL arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin</intervention_name>
    <description>leucovorin 30mg BID day 1 to 7 on in a 2-week cycle</description>
    <arm_group_label>GASL arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Oxaliplatin 75mg/m2 in 250 mL of D5W over 120 minutes IV infusion on day 1 repeated every 14 days</description>
    <arm_group_label>GAP arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A.Cytology or histology confirmed pancreatic adenocarcinoma with evidence of distant&#xD;
             metastasis.&#xD;
&#xD;
          -  B.No history of prior chemotherapy for pancreatic cancer, except adjuvant chemotherapy&#xD;
             that completed at least 6 months before documentation of recurrence by imaging study.&#xD;
&#xD;
          -  C.Patients with prior radiotherapy are eligible if there are other measurable target&#xD;
             lesions that is not irradiated.&#xD;
&#xD;
          -  D.At least one measurable lesion according to RECIST version 1.1&#xD;
&#xD;
          -  E.Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
          -  F.ECOG performance status 0-1&#xD;
&#xD;
          -  G.Age of 20 years or above&#xD;
&#xD;
          -  H.Adequate organ function as defined by the following criteria:&#xD;
&#xD;
        absolute neutrophil count (ANC) ≥ 1,500/mm3 hemoglobin level ≥ 9 g/dL platelet count ≥&#xD;
        100,000/mm3 total bilirubin &lt; 2 mg/dL aspartate aminotransferase (AST) / alanine&#xD;
        aminotransferase (ALT) ≤ 3 x ULN or ≤ 5.0×ULN in the presence of liver metastases&#xD;
        creatinine clearance rate (CCr) ≥ 60 mL/min (24-hour urine collection or calculated by&#xD;
        Cockroft-Gault formula; male: [(140 - age) × weight (kg)]/[72 × serum&#xD;
        creatinine(mg/dL)];female=male x 0.85&#xD;
&#xD;
        -I.Patients with childbearing potential shall have effective contraception for both the&#xD;
        patient and his or her partner during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A. Other malignancy within the past 5 years except for adequately treated localized&#xD;
             skin cancer or carcinoma in situ;&#xD;
&#xD;
          -  B.Active or uncontrolled infection;&#xD;
&#xD;
          -  C.Significant medical conditions that is contraindicated to study medication or render&#xD;
             patient at high risk from treatment complications at physician discretion&#xD;
&#xD;
          -  D.Pregnant women or nursing mothers, or positive pregnancy test for women of&#xD;
             childbearing potential.&#xD;
&#xD;
          -  E.History of active autoimmune disease within 3 years or use of steroid more than&#xD;
             prednisolone 10mg/day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Tzong Chen, MD, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yung-Yeh Su, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yung-Yeh Su, M.D.</last_name>
    <phone>886-6-7000123</phone>
    <phone_ext>65181</phone_ext>
    <email>yysu@nhri.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nai-Jung Chiang, MD, PhD</last_name>
    <phone>886-6-7000123</phone>
    <phone_ext>65148</phone_ext>
    <email>njchiang@nhri.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>800</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Li-Tzong Chen, M.D.</last_name>
      <email>leochen@nhri.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>400</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Li-Yuan Bai, MD, Ph.D</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>5050</phone_ext>
      <email>lybai6@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Li-Yuan Bai, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chang-Fang Chiu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Che-Hung Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Ching Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Min Liao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>600</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan-Shen Shan, MD, Ph.D.</last_name>
      <email>ysshan@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

